Fast-Acting Relief. Zero Injections.
Clinical-strength PT-141 nasal spray, compounded in our U.S.-licensed pharmacy. One spray, clinically dosed — fast-acting, discreet, and designed for your life.
Starting at $165/month
How It Works
Start Online
Answer a few confidential questions. It only takes a few minutes.
Medical Review
A licensed provider reviews your health profile within 24 hours.
Get Prescribed
Custom-compounded PT-141 nasal spray prepared in our U.S.-licensed pharmacy.
Delivered to You
Free discreet shipping. Right to your door.
Why Choose PT-141 Nasal Spray
Fast-Acting Delivery
Nasal delivery means faster absorption. No needles, no waiting — just results when you need them.
Compounded In-House
Our pharmacy compounds every dose. One company, one standard — from consultation to delivery.
Pharmacist Support
Questions? Talk to a real pharmacist. No extra cost, no appointment needed.
What to Expect
PT-141 (bremelanotide) works differently than PDE5 inhibitors — it targets desire at a neurological level
Most patients notice effects within 1–4 hours of administration
One dose can remain effective for 2–3 days
One spray, clinically dosed — no guesswork
Can be used on-demand, not daily
Suitable for patients who haven't responded well to other treatments
Transparent Pricing. No Surprises.
PT-141 Nasal Spray
The MintRx Difference
We own the pharmacy. That means we control quality, speed, and your experience from start to finish.
Hand off to partner pharmaciesOur pharmacy compounds your medicationRound-robin customer serviceOne agent owns your caseAutomated responsesImmediate pharmacist accessWait for complaintsProactive 14-day check-in callsGeneric packagingCustom branding, from box to thank-you cardCommon Questions
What is PT-141?
How do I use the nasal spray?
Is a prescription required?
What about side effects?
Can I cancel anytime?
Do you accept insurance?
Questions? Talk to a real pharmacist.
Book a free 15-minute call. No sales pitch — just answers.
Book a Pharmacist CallNo extra cost. No appointment needed.
